

# Presbyopia - Pipeline Review, H1 2020

<https://marketpublishers.com/r/P3DD9CDA6C0EN.html>

Date: June 2020

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: P3DD9CDA6C0EN

## Abstracts

Presbyopia - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Pipeline Review, H1 2020, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape.

Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Presbyopia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Presbyopia (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 3, 3 and 2 respectively. Presbyopia (Ophthalmology) pipeline guide helps in identifying and tracking emerging

players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Presbyopia (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Presbyopia (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Presbyopia (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for

## Presbyopia (Ophthalmology)

### REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Presbyopia (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Presbyopia (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Presbyopia - Overview
- Presbyopia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Presbyopia - Therapeutics Assessment
  - Assessment by Target
  - Assessment by Mechanism of Action
  - Assessment by Route of Administration
  - Assessment by Molecule Type
- Presbyopia - Companies Involved in Therapeutics Development
  - Allergan Ltd
  - Cellix Bio Pvt Ltd
  - Eyenovia Inc
  - Kedalion Therapeutics Inc
  - Kubota Vision Inc
  - Novartis AG
  - Ocuphire Pharma Inc
  - Orasis Pharmaceuticals Ltd
  - Plex Pharmaceuticals Inc
  - Presbyopia Therapies LLC
  - Reven Pharmaceuticals Inc
  - ViewPoint Therapeutics Inc
- Presbyopia - Drug Profiles
  - (aceclidine + tropicamide) - Drug Profile
    - Product Description
    - Mechanism Of Action
    - R&D Progress
  - (diclofenac sodium + pilocarpine hydrochloride) - Drug Profile
    - Product Description
    - Mechanism Of Action
    - R&D Progress
  - (oxymetazoline hydrochloride + pilocarpine hydrochloride) - Drug Profile
    - Product Description
    - Mechanism Of Action

R&D Progress

(phentolamine mesylate + pilocarpine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGN-241622 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAP-1160 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLXOPH-561 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EV-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KT-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxymetazoline hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pilocarpine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPEC-1004A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Presbyopia and Cataract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VP-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Presbyopia - Dormant Projects

Presbyopia - Product Development Milestones

Featured News & Press Releases

Oct 10, 2019: Orasis Pharmaceuticals announces CSF-1 Eye Drop successfully met primary endpoint in phase 2b clinical study in Presbyopia

Mar 27, 2019: Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia

Nov 27, 2018: Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Board

Aug 02, 2018: Eye drop improves near vision in presbyopia patients

May 05, 2016: Encore Vision Announces Successful Phase I-II Study of Topical EV06 for the Treatment of Presbyopia

May 02, 2016: Encore Vision Announces Positive Results from the Phase I-II Study of Topical EV06 for the Treatment of Presbyopia

Jan 25, 2016: Encore Vision Announces Completion of Target Enrollment

Oct 05, 2015: Encore Vision Announces First Subject Enrolled in Study of Topical Treatment for Presbyopia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Presbyopia, H1 2020  
Number of Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Presbyopia - Pipeline by Allergan Ltd, H1 2020  
Presbyopia - Pipeline by Cellix Bio Pvt Ltd, H1 2020  
Presbyopia - Pipeline by Eyenovia Inc, H1 2020  
Presbyopia - Pipeline by Kedalion Therapeutics Inc, H1 2020  
Presbyopia - Pipeline by Kubota Vision Inc, H1 2020  
Presbyopia - Pipeline by Novartis AG, H1 2020  
Presbyopia - Pipeline by Ocuphire Pharma Inc, H1 2020  
Presbyopia - Pipeline by Orasis Pharmaceuticals Ltd, H1 2020  
Presbyopia - Pipeline by Plex Pharmaceuticals Inc, H1 2020  
Presbyopia - Pipeline by Presbyopia Therapies LLC, H1 2020  
Presbyopia - Pipeline by Reven Pharmaceuticals Inc, H1 2020  
Presbyopia - Pipeline by ViewPoint Therapeutics Inc, H1 2020  
Presbyopia - Dormant Projects, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Presbyopia, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

Allergan Ltd  
Cellix Bio Pvt Ltd  
Eyenovia Inc  
Kedalion Therapeutics Inc  
Kubota Vision Inc  
Novartis AG  
Ocuphire Pharma Inc  
Orasis Pharmaceuticals Ltd  
Plex Pharmaceuticals Inc  
Presbyopia Therapies LLC  
Reven Pharmaceuticals Inc  
ViewPoint Therapeutics Inc



## I would like to order

Product name: Presbyopia - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/P3DD9CDA6C0EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P3DD9CDA6C0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970